Meda previously rejected a takeover offer earlier this month. The company subsequently said it had been contacted with a proposal to combine the two companies, but Meda's board rejected this, too.
The stock was up 2.01% to $51.36 at noon on Friday.
The autoinjector will be free for insured patients and those whose annual income is less than $100,000.
The drug maker's shares have fallen 6.2% since Wednesday's market open.